{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Grade II"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade III-IV"}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"description":"Number of participants who experienced acute GVHD grades II-IV\n\nAcute-GVHD was graded and staged prospectively using criteria from the 1994 Consensus Conference on Acute- GVHD Grading.\n\nGrades are defined as:\n\nGrade II: Skin = rash on 25-50 percent body surface area; Liver = Total Bilirubin 3.1-6.0 mg/dL; Lower GI = Diarrhea 1001-1500 mL/day.\n\nGrade III: Skin = Rash on \\>50% of body surface; Liver = Total Bilirubin 6.1 - 15.0 mg/dL; Lower GI = Diarrhea \\> 1500 mL/day.\n\nGrade IV: Skin = Generalized erythroderma plus bullous formation; Liver = Total Bilirubin \\>15 mg/dL; Lower GI = Severe abdominal pain with or without ileus.\n\nGrade II GVHD as moderate, grade III as severe, and grade IV life-threatening.","groups":[{"description":"Subjects received a nonmyeloablative preparative regimen of alemtuzumab 30mg iv three times a week for two weeks followed by fludarabine 25mg/m\\^2/day for five days followed by a PBPC graft targeted to deliver ≥ 5x10\\^6 CD34+ cells/kg. Cyclosporine A (CSA) for GVHD prophylaxis will be used initially with target CSA levels in the therapeutic range (200 -400 ng/ml).","id":"OG000","title":"Stem Cell Transplant Therapy With Campath-1H"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"up to 100 days","title":"Number of Participants Who Experienced Acute GVHD Grades II-IV","type":"SECONDARY","unitOfMeasure":"Participants"}